FDA Breakthrough Device Designation Granted for Generative AI Radiology Model

Mosaic Clinical Technologies subsidiary Cognita Imaging has earned U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for the Cognita Chest X-Ray (CXR)¹ across multiple critical indications. Cognita CXR is touted as an industry-first generative vision-language model that helps radiologists interpret chest X-rays.

Cognita CXR is reportedly the first radiology generative artificial intelligence (AI) model, and one of the very few radiology AI solutions to secure FDA Breakthrough Designation.² Cognita CXR¹ applies a proprietary, cutting-edge vision-language model to interpret chest X-rays and draft radiology results for physician review. Unlike traditional imaging AI systems that spot the presence of individual findings in isolation, Cognita’s approach analyzes the imaging study and generates comprehensive preliminary findings that are fully-integrated into existing radiology workflows. Licensed radiologists review and finalize the AI-generated findings.

Preliminary internal clinical validation indicates that Cognita CXR can potentially enhance detection and result in significant capacity gains. According to internal clinical validation, radiologists using Cognita CXR achieved up to 16%–65% improved detection rates for certain significant findings, demonstrating the model’s potential to substantially enhance diagnostic accuracy. Preliminary data also showed the potential to boost radiologists’ average interpretation efficiency by 18%.

“Breakthrough Device Designation marks a significant milestone for Cognita CXR,” Mosaic Clinical Technologies Chief Medical Officer Dr. Nina Kottler stated. “It reflects the urgency of the capacity crisis in radiology and provides the opportunity to work closely with the FDA as we advance through the regulatory process. We believe this is an important step toward bringing AI into everyday radiology practice in a way that enables physicians to practice at the top of their license and expands access to high-quality imaging care worldwide.”

The FDA’s Breakthrough Device Program is designed to accelerate the development and review of innovative technologies with the potential to significantly improve patient care. The program is reserved for technologies that could more effectively diagnose or treat life-threatening or irreversibly debilitating conditions. Having earned this designation, Cognita can now benefit from prioritized interactions and closer FDA collaboration to help bring this breakthrough technology to a U.S. healthcare system under an acute diagnostic capacity strain and in urgent need of new solutions.

“Building generative AI that can interpret medical images is one of the most complex challenges in applied AI. Inputs can contain up to 1 billion pixels, encoding entire medical textbooks’ worth of information. On top of this, real-world radiology is defined by corner cases,” Cognita Co-Founder/CEO Dr. Louis Blankemeier stated. “It requires advanced model architectures, method breakthroughs, large-scale, real-world clinical data, and reinforcement learning through continuous radiologist feedback. The FDA’s Breakthrough Device Designation enables closer collaboration as we continue evaluating this approach in clinical settings through Radiology Partners’ network.”

Demand for diagnostic imaging continues to rise globally while the number of radiologists remains constrained. This significant imbalance is leading to a persistent and acute long-term workforce shortage that increases patient wait times, impacts healthcare facility operations, and contributes to diagnostic errors and radiologist burnout. Delays in imaging interpretation can slow downstream care decisions and contribute to bottlenecks across health systems. Cognita is actively developing and validating solutions to assist radiologists in interpreting all X-ray types and 3D computed tomography (CT) imaging across all anatomies, which will be fully incorporated into the Mosaic OS platform.

“Radiology Partners was founded to transform how radiology is practiced and delivered,” Radiology Partners Chairman/CEO Rich Whitney commented. “The Breakthrough Device Designation for Cognita reflects our commitment to pairing great physicians with advanced technology to address the growing demand for diagnostic imaging while meaningfully improving the diagnostic value we offer to clients and patients.”

Cognita is the AI business unit of Mosaic Clinical Technologies, a wholly owned subsidiary of Radiology Partners, the largest U.S. radiology practice that has more than 4,000 radiologists in its network.

Mosaic Clinical Technologies, the technology services division of Radiology Partners (RP), is striving to power the future of radiology through MosaicOS—a proprietary imaging management platform designed to meet the specialty’s most pressing challenges. A fully cloud-native and AI-native operating system, MosaicOS seamlessly integrates diagnostic technologies, AI-powered tools, and smart workflows into a single scalable solution. Mosaic Clinical Technologies supports RP’s national network of affiliated practices and commercial partners across the imaging landscape.

A subsidiary of Mosaic, Cognita is a healthcare AI company attempting to increase the world’s access to healthcare. To achieve this, Cognita’s initial focus is on expanding the capacity and quality of radiology by developing comprehensive AI solutions that help radiologists work more accurately, efficiently, and with greater satisfaction. Cognita combines breakthrough AI innovation with Mosaic Clinical Technologies’ radiology infrastructure solutions and the enterprise scale of Radiology Partners.

Radiology Partners, through its affiliated practices, is a technology-enabled U.S. radiology practice serving more than 3,400 hospitals and other healthcare facilities with high-quality radiology, technology, and artificial intelligence solutions. As a physician-led and physician-owned practice, it strives to transform radiology by innovating across clinical value, technology, service, and economics, while elevating radiology and radiologists in healthcare. Using a proven healthcare services model, Radiology Partners provides consistent, high-quality care to patients, while delivering enhanced value to the hospitals, clinics, imaging centers, and referring physicians.

References
¹ CAUTION: Investigational device. Limited by United States law to investigational use.
² Based on publicly-available information.